| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.
|
J Clin Oncol
|
2009
|
4.54
|
|
2
|
NCCN Clinical Practice Guidelines in Oncology: colon cancer.
|
J Natl Compr Canc Netw
|
2009
|
4.41
|
|
3
|
NCCN Clinical Practice Guidelines in Oncology: rectal cancer.
|
J Natl Compr Canc Netw
|
2009
|
3.37
|
|
4
|
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.
|
J Clin Oncol
|
2012
|
3.36
|
|
5
|
Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.
|
J Clin Oncol
|
2006
|
2.80
|
|
6
|
Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.
|
J Clin Oncol
|
2006
|
2.38
|
|
7
|
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
|
J Clin Oncol
|
2007
|
2.33
|
|
8
|
Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis.
|
Cancer Res
|
2012
|
2.26
|
|
9
|
Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study.
|
Lancet Oncol
|
2009
|
2.23
|
|
10
|
Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer.
|
Clin Cancer Res
|
2005
|
2.13
|
|
11
|
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.
|
J Clin Oncol
|
2008
|
2.04
|
|
12
|
O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.
|
Clin Cancer Res
|
2009
|
2.00
|
|
13
|
Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.
|
J Clin Oncol
|
2006
|
1.86
|
|
14
|
Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer.
|
J Clin Oncol
|
2006
|
1.64
|
|
15
|
Colon cancer, version 3.2014.
|
J Natl Compr Canc Netw
|
2014
|
1.59
|
|
16
|
CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma.
|
Virchows Arch
|
2007
|
1.57
|
|
17
|
Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.
|
Cancer
|
2007
|
1.56
|
|
18
|
Identification of potentially avoidable hospitalizations in patients with GI cancer.
|
J Clin Oncol
|
2014
|
1.51
|
|
19
|
Rectal cancer.
|
J Natl Compr Canc Netw
|
2012
|
1.49
|
|
20
|
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
|
J Clin Oncol
|
2009
|
1.38
|
|
21
|
Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines.
|
J Natl Compr Canc Netw
|
2013
|
1.31
|
|
22
|
Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines.
|
J Natl Compr Canc Netw
|
2013
|
1.17
|
|
23
|
A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors.
|
Dig Dis Sci
|
2006
|
1.09
|
|
24
|
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.
|
PLoS One
|
2012
|
1.05
|
|
25
|
NCCN clinical practice guidelines in oncology. Anal carcinoma.
|
J Natl Compr Canc Netw
|
2010
|
1.00
|
|
26
|
Colon cancer.
|
J Natl Compr Canc Netw
|
2011
|
0.96
|
|
27
|
Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines.
|
J Natl Compr Canc Netw
|
2012
|
0.96
|
|
28
|
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.
|
Cancer
|
2006
|
0.95
|
|
29
|
A Phase II trial of gemcitabine for metastatic neuroendocrine tumors.
|
Cancer
|
2004
|
0.94
|
|
30
|
Adjuvant therapy for gastric cancer: revisiting the past to clarify the future.
|
J Clin Oncol
|
2012
|
0.91
|
|
31
|
Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer.
|
Oncologist
|
2013
|
0.87
|
|
32
|
The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer.
|
Am J Clin Oncol
|
2006
|
0.86
|
|
33
|
Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer.
|
Cancer Chemother Pharmacol
|
2006
|
0.86
|
|
34
|
Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer.
|
Clin Colorectal Cancer
|
2006
|
0.85
|
|
35
|
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.
|
J Natl Compr Canc Netw
|
2017
|
0.83
|
|
36
|
Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer.
|
Oncologist
|
2013
|
0.83
|
|
37
|
Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapy.
|
J Clin Oncol
|
2005
|
0.81
|
|
38
|
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer.
|
Cancer Chemother Pharmacol
|
2007
|
0.81
|
|
39
|
Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer.
|
Clin Colorectal Cancer
|
2006
|
0.80
|
|
40
|
A Phase II trial of vinorelbine in patients with advanced gastroesophageal adenocarcinoma.
|
Cancer Invest
|
2006
|
0.79
|
|
41
|
A phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagus.
|
Cancer Invest
|
2006
|
0.79
|
|
42
|
A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer.
|
Invest New Drugs
|
2011
|
0.77
|
|
43
|
Should people with Barrett's esophagus, who are at risk for cancer of the esophagus, avoid alcohol?
|
Health News
|
2004
|
0.75
|
|
44
|
A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer.
|
Cancer Invest
|
2003
|
0.75
|